Table 2. . Use of therapeutic drugs by patients with rheumatoid arthritis at baseline and 6 and 12 months.
|
Concomitant drug |
6 months (n = 196) |
12 months (n = 151) |
||||||
|---|---|---|---|---|---|---|---|---|
| Total, n (%) | Adalimumab, n = 143 (%) | Etanercept, n = 53 (%) | Valor p-value | Total, n (%) | Adalimumab, n = 109 (%) | Etanercept, n = 42 (%) | p-value | |
| Corticosteroid |
133 (68) |
96 (67) |
37 (70) |
0.721 |
103 (68) |
75 (70) |
28 (67) |
0.800 |
| NSAID |
70 (36) |
49 (34) |
21 (40) |
0.487 |
52 (34) |
40 (37) |
12 (29) |
0.346 |
| sDMARD |
130 (66) |
91 (64) |
39 (74) |
0.191 |
100 (66) |
69 (63) |
31 (74) |
0.221 |
| Methotrexate |
69 (35) |
42 (29) |
27 (51) |
0.005* |
58 (38) |
34 (31) |
24 (57) |
0.003* |
| Leflunomide | 60 (31) | 49 (34) | 11 (21) | 0.068 | 41 (27) | 33 (30) | 8 (19) | 0.165 |
*p < 0.05.
sDMARD: Synthetic disease-modifying antirheumatic drug.